Pharmacokinetics and Mechanism of Intestinal Absorption of JBP485 in Rats

Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 5, 2010, Pages 500-507

  Cang, Jian ^a   Zhang, Jian ^a   Wang, Changyuan ^a   Liu, Qi ^a   Meng, Qiang ^a   Wang, Desheng ^b   Sugiyama, Yuichi ^b   Tsuji, Akira ^c   Kaku, Taiichi ^d   Liu, Kexin ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TOKYO   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

^d Japan Bioproducts Industry Co Ltd   (Japan)

Author keywords

Dipeptide; Glycylsarcosine; JBP485; PEPT1; Pharmacokinetics

Indexed keywords

CYCLO TRANS HYDROXYPROLYL SERINE; DIPEPTIDE; GLYCYLSARCOSINE; JBP 485; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG UPTAKE; FIRST PASS EFFECT; INTESTINE ABSORPTION; NONHUMAN; RAT;

EID: 78449237500     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-10-RG-045     Document Type: Article

References (22)

1. Yagi, A., Nagao, Okamura, N., Ishizu, T., Itoh, H. and Shida, T.: Effect of cyclo (trans-4-L-hydroxyprolyl-L-serine) from hydrolysate of human placenta on baby hamsterkidney -21/C-13 cells. Nat. Med., 52: 156-159 (1998).
2. Liu, K. X., Okazawa, I. and Kaku, T. I.: Effect of Laennec on liver regeneration (in Japanese). Clin. Pharmacol. Ther., 5: 2187-2194 (1995).
3. Liu, K. X., Kato, Y., Kaku, T. I., Santa, T., Imai, K., Yagi, A., Ishizu, T. and Sugiyama, Y.: Hydroxyprolylserine derivatives JBP923 and JBP485 exhibit the antihepatitis activities after gastrointestinal absorption in rats. J. Pharmacol. Exp. Ther., 294: 510-515 (2000).
4. Wu, J. J.,Wang, C. Y., Liu, Q., Yang, T., Zhang, Q. H., Peng, J. Y., Gao, Y., Sun, H. J., Kaku, T. I. and Liu, K. X.: Protective effect of JBP485 on concanavalin A-induced hepatocyte toxicity in primary cultured rat hepatocytes. Eur. J. Pharmacol., 589: 299-305 (2008)
5. Yang, T.,Wu, J. J., Liu, Q.,Wang, C. Y., Ma, X. C., Peng, J. Y., Kaku, T. I. and Liu, K. X.: Protective effect of JBP485 on concanavalin A-induced liver injury in mice. J. Pharm. Pharmacol., 61: 767-774 (2009).
6. +/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm. Res., 16: 55-61 (1999).
7. Shu, C., Shen, H., Hopfer, U. and Smith, D. E.: Mechanism of intestinal absorption and renal reabsorption of an orally active ace inhibitor: uptake and transport of fosinopril in cell cultures. Drug Metab. Dispos., 29: 1307-1315 (2001).
8. Zhu, T., Chen, X. Z., Steel, A., Hediger, M. A. and Smith, D. E.: Differential recognition of ACE inhibitors in Xenopus laevis oocytes expressing rat PEPT1 and PEPT2. Pharm. Res., 17: 526-532 (2000).
9. Brodin, B., Nielsen, C. U., Steffansen, B. and Frokjaer, S.: Transport of peptidomimetic drugs by the intestinal di/tri-peptide transporter, PepT1. Pharmacol. Toxicol., 90: 285-296 (2002).
10. +/peptide symporter PEPT1: structure-affinity relationships. Eur. J. Pharm. Sci., 21: 53-60 (2004).
11. Daniel, H. and Kottra, G.: The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch., 447: 610-618 (2004).
12. Biegel, A., Knütter, I., Hartrodt, B., Gebauer, S., Theis, S., Luckner, P., Kottra, G., Rastetter, M., Zebisch, K., Thondorf, I., Daniel, H., Neubert, K. and Brandsch, M.: The renal type H+/peptide symporter PEPT2: structure-affinity relationships. Amino Acids., 31: 137-156 (2006a)
13. +-independent transport systems in T84 and Caco-2 cells. Biochim. Biophys. Acta. Biomembr., 1419: 15-22 (1999).
14. Hidalgo, I. J., Raub, T. J. and Borchardt, R. T.: Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology., 96: 736-749 (1989).
15. Wilson, T. H. and Wiseman, G.: The use of sacs of everted small intestine for the study of transference of substances from the mucosal to the serosal surface. J. Physiol., 123: 116-125 (1954).
16. Zhang, Q. H., Liu, Q.,Wu, J. J.,Wang, C. Y., Peng, J. Y.,Ma, X. C. and Liu, K. X.: PEPT1 involved in the uptake and transepithelial transport of cefditoren in vivo and in vitro. Eur. J. Pharmacol., 612: 9-14 (2009).
17. Souli, A., Chariot, J., Voisin, T., Presset, O., Tsocas, A., Balasubramaniam, A., Laburthe, M. and Rozé, C.: Several recap tors mediate the antisecretory effect of peptide YY, neuropeptide Y, and pancreatic polypeptide on VIP-induced fluid secretion in the rat jejunum in vivo. Peptides., 18: 551-557 (1997).
18. Tavelin, S., Gråsjoä, J., Taipalensuu, J., Ocklind, G. and Artursson, P.: Applications of epithelial cell culture in studies of drug transport. Methods Mol. Biol., 188: 233-272 (2002).
19. Nakanishi, T., Tamai, I., Takaki, A. and Tsuji, A.: Cancer celltargeted drug delivery utilizing oligopeptide transport activity. Int. J. Cancer., 88: 274-280 (2000).
20. Endres, C. J., Hsiao, P., Chung, F. S. and Unadkat, J. D.: The role of transporters in drug interactions. Eur. J. Pharml. Sci., 27: 501-517 (2006).
21. Shimizu, R., Sukegawa, T., Tsuda, Y. and Itoh, T.: Quantitative prediction of oral absorption of PEPT1 substrates based on in vitro uptake into Caco-2 cells. Int. J. Pharm., 354: 104-110 (2008).
22. Zhang, J., Wang, C. Y., Liu, Q., Meng, Q., Cang, J., Sun, H. S., Gao, Y., Kaku, T. I. and Liu, K. X.: Pharmacokinetic Interaction between JBP485 and Cephalexin. Drug Metab Dispos., 38: 930-938 (2010).